home / stock / mrtx / mrtx news

MRTX News and Press, Mirati Therapeutics Inc. From 10/08/23

Stock Information
Company Name: Mirati Therapeutics Inc.
Stock Symbol: MRTX
Market: NASDAQ
Website: mirati.com
Menu
MRTX MRTX Quote MRTX Short MRTX News MRTX Articles MRTX Message Board
Get MRTX Alerts

News, Short Squeeze, Breakout and More Instantly...
MRTX - Bristol-Myers Squibb to acquire Mirati Therapeutics for $4.8B

2023-10-08 17:52:39 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript As F...
MRTX - Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRAS G12C Inhibitor Approved by the U.S. FDA for the Treatment of P...

MRTX - As FDA mulls fate of Amgen drug, Sanofi could snap up rival Mirati

2023-10-08 15:18:00 ET As the FDA continues to mull the fate of Amgen's lung cancer drug Lumakras, Sanofi is reportedly moving in on Mirati ( NASDAQ: MRTX ), which has developed a rival product called Krazati. Analysts appear to be divided on whether the FDA will end up denying ...

MRTX - FDA panel finds results from key Amgen Lumakras study unreliable

2023-10-05 15:13:58 ET More on Amgen Amgen Inc. (AMGN) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript) Amgen Inc. (AMGN) Citi Global Healthcare Conference (Transcript) Amgen: Not An Investment Mistake, But It Was Better Before Amgen ...
MRTX - Mirati Therapeutics soars on report of Sanofi takeover interest

2023-10-05 14:35:52 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript Mira...

MRTX - Mirati stock up 9% amid FDA meeting on rival Amgen drug

2023-10-05 12:48:51 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript Jone...

MRTX - Jones Research sees Amgen FDA issues reading through to Mirati

2023-10-03 16:35:34 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript Mira...
MRTX - Catalyst Watch: Tesla deliveries, Google event, Kellogg spinoff, Amgen drama and Ether ETFs

2023-09-29 15:00:29 ET More on the markets Historical Evidence Between Real Yields Suggests Further Slump For SPY Interest Rates Won't Be Higher For Longer: SPY Implications Rate environment today 'rhymes with 2008' - J.P. Morgan's Kolanovic Stocks in midst o...

MRTX - Mirati stock climbs 10% ahead of data presentation, FDA meeting on rival drug

2023-09-28 16:18:43 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript Mira...

MRTX - Mirati To Present Updated Clinical Data at ESMO Congress 2023

Mirati To Present Updated Clinical Data at ESMO Congress 2023 PR Newswire Late-Breaking KRYSTAL-7 data demonstrates compelling efficacy and safety of adagrasib in combination with pembrolizumab in 1L NSCLC Data follows recent inclusion of the adagrasib in co...
Previous 10 Next 10